Royalty Report: Drugs, Biotechnology, Diagnostic – Collection: 27122

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Biotechnology
  • Diagnostic
  • Cancer
  • Antibody
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27122

License Grant
The Company hereby grants to Licensee, including its Affiliates a non-exclusive, non-transferable, royalty bearing license, with no right to sublicense third parties, under the Patent Rights and to use the Know-How to make, use and sell Licensed Products solely for use in the Field of the Agreement in the Licensed Territory.
License Property
The Cell Lines and methods employed to produce and isolate a monoclonal antibody product from these cell lines including in vitro and in vivo cell culture.

term 'Licensed Products' means products containing Monoclonal Antibodies defined above and promoted and labelled for use as laboratory reagents.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 163133

License Grant
Licensor grants a Sublicense to Licensee and its Affiliates, to use the Licensor Antibodies, Cell Lines and Derivatives for the purpose of making, having made, using, selling and having sold Licensee Products.  Licensor shall provide Licensee quantities of Licensor Antibodies or Cell Lines and Derivatives, and information relating thereto.  Licensor agrees to deliver additional viable aliquots of Cell Lines or Derivatives to replace any aliquots previously delivered, which have subsequently become incapable of producing Licensor Monoclonal Antibodies and which are the same as the Licensor Cell Lines or Derivatives previously received by Licensee.

In order to protect Licensees source of supply of the Cell Lines or Derivatives Licensor warrants and agrees that Licensor shall maintain the Cell Lines and Derivatives in such a manner as will best preserve the viability thereof, in accordance with established scientific procedures.

License Property
Licensor holds exclusive licenses with respect to the Antibodies. Licensor is a supplier of specialty reagents, immuno-assay test kits and molecular research products to customers involved in biomedical research, the biotechnology industry and pharmaceutical drug discovery.

Monoclonal Antibodies to Human Interferongamma:
        *1.       Antibody B133.5

         2.       Antibody 3C11C8

         3.       Antibody 2G1

Monoclonal Antibodies to Human Granulocyte Marophage-Colony Stimulating Factor:

         1.       Antibody 3092

         2.       Antibody 3034

         3.       Antibody 1089

         4.       Antibody 4117

         5.       Antibody 2118

         6.       Antibody 1028

Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha:

         *1.      Antibody B154.7.1

         *2.      Antibody B154.9.1

Field of Use
The purpose for this agreement is for research use.

IPSCIO Record ID: 29291

License Grant
The Licensor granted a limited, nontransferable, worldwide patent license, without the right to sublicense, to use the Antibodies solely for the purpose of making and selling the Licensee's Products only in the Research Market.
License Property
Licensor owns and controls certain organisms (cell lines) used in the production of monoclonal antibodies. Monoclonal Antibodies to Human Interferongamma; Monoclonal Antibodies to Human Granulocyte Macrophage-Colony Stimulating Factor; Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha.
Field of Use
Licensee wishes to sell products containing the Monoclonal Antibodies for research use only.

IPSCIO Record ID: 6804

License Grant
The Licensor has a non-exclusive licensing Agreement with the Licensee for the use of hybridoma cell lines that are proprietary to the Licensor.
License Property
The cell lines generate monoclonal antibodies used in the Licensee's products.  

The Licensor provides vital products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. Their portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services.

IPSCIO Record ID: 26091

License Grant
University grants Company a sole and exclusive worldwide License, under the Technology, Existing Patent Rights (to the extent not owned by the Company) and Developed Patent Rights  to make, have made, use and sell Product and Process,  including the right to grant sublicenses.
License Property
Existing Patent Rights shall mean (i) A Method for Isolating, Purifying and Culturally Expanding Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 615,430); (ii) Monoclonal Antibodies Specific for Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 716,917); (iii) A Method and Device for Enhancing the Implantation and Differentiation of Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 614,915); and (iv) A Method and Device for Treating Connective Tissue Disorders (U.S. Patent Application No. 614,912); any division, continuation, or continuation-in-part thereof and any foreign patent application or equivalent corresponding thereto and any Letters Patent or the equivalent thereof in any country of the world.

Developed Patent Rights shall mean any and all patents and patent applications anywhere in the world which contains one or more claims directed to Technology, which is not an Existing Patent Right.

Technology shall mean any and all existing or future information, technical data, inventions, discoveries or know-how, and materials whether or not patented or patentable, related to or useful for the  identification, isolation, purification, propagation or of use of mesenchymal stem cells and/or cells or products derived from or produced by mesenchymal stem cells, which are conceived, developed or reduced to practice by an Investigator while performing research at the University.

IPSCIO Record ID: 7481

License Grant
Licensor hereby grants to Licensee a worldwide exclusive royalty bearing license in the Field to the non-exclusive rights held by Licensor with respect to the TGF-B Antibody Patent Rights to (i) use the TGF-B Antibody Know How, and (ii) to make, have made, use, offer to sell, sell or import into the United States Licensed Product(s) or use Licensed Method(s) in the Territory in which the TGF-B Antibody Patent Rights are effective until the end of the full term(s) for which these Patent Rights are issued, unless sooner terminated as hereinafter provided.
License Property
Licensor is a biopharmaceutical company that is the owner of a certain patent and patent applications and know how relating to monoclonal antibodies that bind Transforming Growth Factor B ('TGF-B'), specifically TGF-B1 and TGF-B2.

Biological Property shall mean any DNA materials, derivatives of such DNA materials, cell lines and peptides containing the DNA materials or derivatives thereof, that are related to the TGF-B Antibody Patent Rights, and to the TGF-B Receptor Patent Rights, respectively.

TGF-B Antibody Patent Rights shall mean the Patent Rights that relate to monoclonal antibodies that bind Transforming Growth Factor ('TGF-B'), specifically TGF-B1 and TGF-B2.

TGF-B Receptor Patent Rights Licensed from MIT shall mean the Patent Rights that relate to TGF-B receptors, including TGF-B type II and TGF-B type III receptors, cDNA of the respective receptors, and methods of use.

Field of Use
Field shall mean uses for any and all purposes with the following exceptions: (i) opthamology, (ii) the TGF-B Antibody Rights previously licensed to Genentech, Inc., and (iii) with respect to the TGF-B Receptor Patent Rights Licensed from MIT only, those rights previously exclusively sublicensed by CELTRIX to R&D Systems.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.